Back to search results

Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy

This study is looking at whether adding cyclobenzaprine (Flexeril®) to standard pain relief helps women after a minimally invasive hysterectomy (surgery to remove the uterus). Cyclobenzaprine is already approved by the FDA for muscle spasms. Researchers want to see if it can improve pain control and reduce the need for strong pain medications after this type of surgery. You may be able to join if you are a woman over 18, speak English, and are having a total laparoscopic hysterectomy. The main goal is to see how much pain you have on the third day after surgery. The study plans to include 36 participants, but its current status is unclear.

Study design
This study is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 36 women.
What's involved
Participants will take 5mg of cyclobenzaprine three times a day for one week after their surgery.
Compensation
Not stated in the trial record.
Follow-up
Your pain will be measured on the third day after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07664956

Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy

Not Yet Recruiting
PHASE4Ages 18+InterventionalTreatment
Christiana Care Health Services
~36 participants
Updated 2026-06-24 on ClinicalTrials.gov
What's tested:Cyclobenzaprine

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Visual Analog Scale (VAS) Pain Score on Post Op Day 3
Measured over 3 days postoperatively

Conditions

Minimally Invasive Surgical Procedures
Abnormal Uterine Bleeding, Unspecified
Adenomyosis of Uterus
Fibroid Uterus
Chronic Pelvic Pain
Endometriosis
Menorrhagia
Endometritis
Adnexal Diseases

Explore related trials

Abnormal uterine bleedingAdnexal DiseasesEndometriosisEndometritisMenorrhagiaPelvic PainPost-Operative PainUterine Corpus AdenomyosisUterine Corpus Leiomyoma

NCT07664956

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • ChristianaCare Health System

    Newark, Delawareno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Margaret Wingo, MD
[email protected]
302-623-4410
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>18yo
Female
English speaking
Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy
If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included
Surgery took place at ChristianaCare Hospitals
No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine

Exclusion

Age \<18yo
Male
Pregnant, breastfeeding
Non-English speaking
Primary procedures other than laparoscopic hysterectomy
Laparoscopic myomectomy
Laparoscopic resection of endometriosis
Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy
Hysteroscopic procedures
Bartholin gland marsupialization
Operations that are scheduled as or converted to the open approach
Procedures with planned or unplanned bladder or bowel surgery
Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage/failure, bariatric surgery, history of gastric ulcer, etc.
Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management
Currently undergoing medication assisted treatment for opioid use disorder
Currently using opioids consistently
Allergies or contraindications to cyclobenzaprine:
Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome
Allergies or contraindications to inactive ingredients in Flexeril, such as lactose
Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates

What this trial measures

  • Visual Analog Scale (VAS) Pain Score on Post Op Day 33 days postoperatively

    The primary objective of the study will be to assess pain scores via Visual Analog Scale (VAS) on Post Op Day 3 compared between the control group vs cyclobenzaprine group. Ratings will be from 0 to 10, which are associated with visual cues to aid in selection. As stated above, VAS pain scores will be collected electronically via REDCap. The survey will be distributed via Doximity text or patient portal message.